NCT07148050View on ClinicalTrials.gov

Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

December 15, 2025

Primary Completion Date

April 15, 2029

Study Completion Date

April 15, 2044

Conditions
Solid Tumor (Excluding CNS)Liver Cell CarcinomaMalignant Rhabdoid TumorYolk Sac TumorLiposarcomaRhabdomyosarcomaEmbryonal Sarcoma of LiverWilms TumorHepatocellular CarcinomaHepatoblastoma
Interventions
BIOLOGICAL

SC-CAR.GPC3xIL15.21 CAR T cells

Autologous SC-CAR.GPC3xIL15.21 T cell products infusion

Trial Locations (1)

98105

Seattle Children's Hospital, Seattle

All Listed Sponsors
lead

Seattle Children's Hospital

OTHER